Plant Name: Oyedaea verbesinoides
Collective Molecular Activities at 10μM Activity Cutoff
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
| Cytochrome P450 Enzymes: |
|---|
Detailed Information of Human Protein Targets
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| BP | GO:0050896; response to stimulus | GO:0042738; exogenous drug catabolic process | 1.494E-12 | 2.958E-09 | CYP1A2, CYP2A6, CYP2C19, CYP2C9, CYP3A4 |
| MF | GO:0003824; catalytic activity | GO:0008395; steroid hydroxylase activity | 2.456E-12 | 4.456E-09 | CYP2A13, CYP2A6, CYP2C19, CYP2C9, CYP2D6, CYP3A4 |
| MF | GO:0005488; binding | GO:0019825; oxygen binding | 1.474E-11 | 2.293E-08 | CYP1A2, CYP2A13, CYP2C19, CYP2C9, CYP2D6, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 3.811E-11 | 5.187E-08 | CYP1A2, CYP2A13, CYP2A6, CYP2C19, CYP2C9 |
| MF | GO:0005488; binding | GO:0020037; heme binding | 1.499E-10 | 1.717E-07 | CYP1A2, CYP2A13, CYP2A6, CYP2C19, CYP2C9, CYP2D6, CYP3A4 |
| MF | GO:0005488; binding | GO:0005506; iron ion binding | 7.211E-10 | 6.542E-07 | CYP1A2, CYP2A13, CYP2A6, CYP2C19, CYP2C9, CYP2D6, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0070989; oxidative demethylation | 9.011E-10 | 7.849E-07 | CYP1A2, CYP2C9, CYP2D6, CYP3A4 |
| MF | GO:0005488; binding | GO:0008270; zinc ion binding | 1.038E-09 | 8.690E-07 | CA1, CA12, CA2, CA3, CA5A, CA5B, CA6, CA7, CA9, NR1H4, THRB |
| BP | GO:0008152; metabolic process | GO:0006805; xenobiotic metabolic process | 4.567E-09 | 2.842E-06 | CYP1A2, CYP2A13, CYP2C19, CYP2C9, CYP2D6, CYP3A4 |
| MF | GO:0003824; catalytic activity | GO:0008392; arachidonic acid epoxygenase activity | 4.315E-09 | 2.842E-06 | CYP2A13, CYP2A6, CYP2C19, CYP2C9 |
| MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 6.736E-09 | 3.964E-06 | CYP1A2, CYP2C9, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0008202; steroid metabolic process | 1.477E-08 | 8.038E-06 | CYP1A2, CYP2A6, CYP2C19, CYP2C9, CYP2D6, CYP3A4, NR1H4 |
| MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 1.597E-08 | 8.483E-06 | CYP1A2, CYP2A13, CYP2D6, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0009804; coumarin metabolic process | 5.879E-08 | 2.845E-05 | CYP2A13, CYP2A6, CYP2D6 |
| BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 2.011E-07 | 8.936E-05 | CYP1A2, CYP2C19, CYP2C9 |
| MF | GO:0003824; catalytic activity | GO:0008389; coumarin 7-hydroxylase activity | 1.480E-06 | 5.858E-04 | CYP2A13, CYP2A6 |
| MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 2.953E-27 | 6.430E-23 | CA1, CA12, CA14, CA2, CA3, CA5A, CA5B, CA6, CA7, CA9 |
| BP | GO:0008152; metabolic process | GO:0009822; alkaloid catabolic process | 4.435E-06 | 1.637E-03 | CYP2D6, CYP3A4 |
| BP | GO:0009987; cellular process | GO:0032849; positive regulation of cellular pH reduction | 4.435E-06 | 1.637E-03 | CA2, CA7 |
| BP | GO:0009987; cellular process | GO:0071276; cellular response to cadmium ion | 7.404E-06 | 2.655E-03 | CYP1A2, EGFR, MAPK1 |
| BP | Unclassified; | GO:0032846; positive regulation of homeostatic process | 7.436E-06 | 2.655E-03 | CA2, CA7, EGFR, MAPK1, NR1H4 |
| CC | GO:0016020; membrane | GO:0005789; endoplasmic reticulum membrane | 9.627E-06 | 3.225E-03 | CYP1A2, CYP2A13, CYP2A6, CYP2C19, CYP2C9, CYP2D6, CYP3A4, EGFR |
| MF | GO:0003824; catalytic activity | GO:0004064; arylesterase activity | 2.213E-05 | 7.085E-03 | CA1, CA2 |
| MF | GO:0060089; molecular transducer activity | GO:0004887; thyroid hormone receptor activity | 3.095E-05 | 9.768E-03 | NR1H4, THRB |
| BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 2.394E-21 | 2.606E-17 | CA1, CA12, CA14, CA2, CA3, CA5A, CA5B, CA6, CA7, CA9 |
| BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 1.173E-19 | 6.386E-16 | CA1, CA12, CA2, CA3, CA5A, CA5B, CA6, CA7, CA9 |
| BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 1.138E-14 | 2.753E-11 | CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4 |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10, ordered by adjusted p-value
Detailed Information of Enriched KEGG Pathways
| Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|
| hsa00910 | Nitrogen metabolism_Homo sapiens_hsa00910 | 1.349E-26 | 1.538E-24 | CA12; CA1; CA3; CA5B; CA2; CA5A; CA7; CA6; CA9; CA14 |
| hsa00982 | Drug metabolism - cytochrome P450_Homo sapiens_hsa00982 | 1.730E-10 | 9.308E-09 | CYP2C9; CYP2A6; CYP2D6; CYP1A2; CYP3A4; CYP2C19 |
| hsa00980 | Metabolism of xenobiotics by cytochrome P450_Homo sapiens_hsa00980 | 2.449E-10 | 9.308E-09 | CYP2C9; CYP2A6; CYP2A13; CYP2D6; CYP1A2; CYP3A4 |
| hsa05204 | Chemical carcinogenesis_Homo sapiens_hsa05204 | 5.003E-10 | 1.426E-08 | CYP2C9; CYP2A6; CYP2A13; CYP1A2; CYP3A4; CYP2C19 |
| hsa00591 | Linoleic acid metabolism_Homo sapiens_hsa00591 | 3.712E-08 | 8.463E-07 | CYP2C9; CYP1A2; CYP3A4; CYP2C19 |
| hsa00830 | Retinol metabolism_Homo sapiens_hsa00830 | 1.028E-06 | 1.953E-05 | CYP2C9; CYP2A6; CYP1A2; CYP3A4 |
| hsa04726 | Serotonergic synapse_Homo sapiens_hsa04726 | 9.082E-06 | 1.479E-04 | CYP2C9; CYP2D6; MAPK1; CYP2C19 |
| hsa04976 | Bile secretion_Homo sapiens_hsa04976 | 8.225E-05 | 1.042E-03 | CA2; NR1H4; CYP3A4 |
| hsa05223 | Non-small cell lung cancer_Homo sapiens_hsa05223 | 2.043E-03 | 1.663E-02 | MAPK1; EGFR |
| hsa05219 | Bladder cancer_Homo sapiens_hsa05219 | 1.100E-03 | 1.140E-02 | MAPK1; EGFR |
| hsa05213 | Endometrial cancer_Homo sapiens_hsa05213 | 1.764E-03 | 1.547E-02 | MAPK1; EGFR |
| hsa05214 | Glioma_Homo sapiens_hsa05214 | 2.741E-03 | 1.746E-02 | MAPK1; EGFR |
| hsa00983 | Drug metabolism - other enzymes_Homo sapiens_hsa00983 | 1.383E-03 | 1.314E-02 | CYP2A6; CYP3A4 |
| hsa00590 | Arachidonic acid metabolism_Homo sapiens_hsa00590 | 2.497E-03 | 1.746E-02 | CYP2C9; CYP2C19 |
| hsa04320 | Dorso-ventral axis formation_Homo sapiens_hsa04320 | 4.756E-04 | 5.422E-03 | MAPK1; EGFR |
| hsa05212 | Pancreatic cancer_Homo sapiens_hsa05212 | 2.825E-03 | 1.746E-02 | MAPK1; EGFR |
| hsa05218 | Melanoma_Homo sapiens_hsa05218 | 3.260E-03 | 1.858E-02 | MAPK1; EGFR |
| hsa00140 | Steroid hormone biosynthesis_Homo sapiens_hsa00140 | 2.190E-03 | 1.664E-02 | CYP1A2; CYP3A4 |
| hsa05230 | Central carbon metabolism in cancer_Homo sapiens_hsa05230 | 2.909E-03 | 1.746E-02 | MAPK1; EGFR |
| hsa04012 | ErbB signaling pathway_Homo sapiens_hsa04012 | 4.851E-03 | 2.409E-02 | MAPK1; EGFR |
| hsa05215 | Prostate cancer_Homo sapiens_hsa05215 | 5.071E-03 | 2.409E-02 | MAPK1; EGFR |
| hsa04520 | Adherens junction_Homo sapiens_hsa04520 | 3.536E-03 | 1.920E-02 | MAPK1; EGFR |
| hsa04912 | GnRH signaling pathway_Homo sapiens_hsa04912 | 5.295E-03 | 2.415E-02 | MAPK1; EGFR |
| hsa04915 | Estrogen signaling pathway_Homo sapiens_hsa04915 | 6.236E-03 | 2.734E-02 | MAPK1; EGFR |
| hsa04540 | Gap junction_Homo sapiens_hsa04540 | 4.961E-03 | 2.409E-02 | MAPK1; EGFR |
| hsa05231 | Choline metabolism in cancer_Homo sapiens_hsa05231 | 6.482E-03 | 2.737E-02 | MAPK1; EGFR |
| hsa04066 | HIF-1 signaling pathway_Homo sapiens_hsa04066 | 6.733E-03 | 2.741E-02 | MAPK1; EGFR |
| hsa04919 | Thyroid hormone signaling pathway_Homo sapiens_hsa04919 | 8.752E-03 | 3.440E-02 | THRB; MAPK1 |
| hsa04210 | Apoptosis_Homo sapiens_hsa04210 | 1.214E-02 | 4.325E-02 | LMNA; MAPK1 |
| hsa01100 | Metabolic pathways_Homo sapiens_hsa01100 | 1.433E-02 | 4.803E-02 | CYP2C9; CYP2A6; CYP1A2; CYP2C19; CYP3A4 |
| hsa05160 | Hepatitis C_Homo sapiens_hsa05160 | 1.101E-02 | 4.048E-02 | MAPK1; EGFR |
| hsa04068 | FoxO signaling pathway_Homo sapiens_hsa04068 | 1.101E-02 | 4.048E-02 | MAPK1; EGFR |
| hsa04072 | Phospholipase D signaling pathway_Homo sapiens_hsa04072 | 1.281E-02 | 4.425E-02 | MAPK1; EGFR |
| hsa04921 | Oxytocin signaling pathway_Homo sapiens_hsa04921 | 1.527E-02 | 4.975E-02 | MAPK1; EGFR |
| hsa00232 | Caffeine metabolism_Homo sapiens_hsa00232 | 1.377E-05 | 1.962E-04 | CYP2A6; CYP1A2 |
Human Diseases Associated with the Target Proteins of the Plant (Activity≤10μM)
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Linked Targets |
|---|---|---|---|
| C00-D49: Neoplasms | Thyroid cancer diagnosis | C73 | TSHR |
| NA: NA | Edema | NA | CA2 |
| I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CA2; CYP2D6 |
| C00-D49: Neoplasms | Inflammatory breast cancer | C50 | EGFR |
| C00-D49: Neoplasms | Urethral cancer | NA | EGFR |
| C00-D49: Neoplasms | Locally advanced head and neck cancer | C07-C14, C32, C33 | EGFR |
| C00-D49: Neoplasms | Lung cancer | C33-C34 | EGFR |
| W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Diagnostic test to differentiate primary and secondary hypothyroidism | W88 | TSHR |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | CA9; MAPK1; EGFR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Lipid metabolism disorder | E75-E78 | THRB |
| E00-E89: Endocrine, nutritional and metabolic diseases | High cholesterol levels in blood | E78.0 | THRB |
| I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Diabetic foot ulcer | L88-L89 | EGFR |
| C00-D49: Neoplasms | Ovarian cancer | C56 | EGFR; EGFR |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Vulnerary | S00-T98 | EGFR |
| A00-B99: Certain infectious and parasitic diseases | Bacterial infections | A00-B99 | CYP2C9 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperlipidaemia | E78 | THRB |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperthyroidism | E05 | THRB |
| A00-B99: Certain infectious and parasitic diseases | Cryptosporidium infection | A07.2 | EGFR |
| K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA2; CA1 |
| C00-D49: Neoplasms | Non-small-cell lung cancer | NA | EGFR |
| C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | EGFR; EGFR |
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | CA2 |
| K00-K95: Diseases of the digestive system | Gastrointestinal disease | K00-K93 | EGFR |
| C00-D49: Neoplasms | Glioblastoma multiforme | C71 | EGFR; EGFR |
| C00-D49: Neoplasms | Glioma | C71 | EGFR; EGFR |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | CA1; CA1 |
| C00-D49: Neoplasms | Thyroid cancer | C73 | TSHR |
| C00-D49: Neoplasms | Colon cancer | C50 | EGFR |
| C00-D49: Neoplasms | Head and neck squamous cell carcinoma | C44 | EGFR |
| C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | EGFR; EGFR; EGFR |
| C00-D49: Neoplasms | Advanced cancers | C00-C96 | EGFR |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Wound healing | T14.0-T14.1 | THRB |
| C00-D49: Neoplasms | Colorectal cancer | C18-C21 | EGFR; EGFR |
| C00-D49: Neoplasms | Gastric cancer | C16 | EGFR; EGFR |
| C00-D49: Neoplasms | Lymphoma | C81-C86 | CA9; EGFR |
| A00-B99: Certain infectious and parasitic diseases | Malaria | B54 | CYP2D6 |
| C00-D49: Neoplasms | Chronic lymphocytic leukaemia | C91 | EGFR |
| C00-D49: Neoplasms | Clear cell renal cell carcinoma | C64 | CA9 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hypothyroidism | E03 | THRB |
| I00-I99: Diseases of the circulatory system | Cerebrovascular ischaemia | I61-I63 | EGFR |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | CYP3A4 |
| H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | CA1 |
| C00-D49: Neoplasms | Melanoma | C43 | EGFR |
| C00-D49: Neoplasms | Malignant tumor | C00-C75, C7A, C7B | EGFR |
| C00-D49: Neoplasms | Pancreatic cancer | C25 | EGFR |
| C00-D49: Neoplasms | Renal cancer | C64 | CA9 |
| I00-I99: Diseases of the circulatory system | Restenosis | I51.89 | MAPK1 |
| C00-D49: Neoplasms | Cancer | C00-C96 | CA1; CA9; MAPK1; EGFR |
| C00-D49: Neoplasms | Refractory breast cancer | C50 | EGFR |
| G00-G99: Diseases of the nervous system G00-G99 | Migraine | G43 | CYP2D6 |
| C00-D49: Neoplasms | Metastatic colorectal cancer | C18-C21 | EGFR |
| C00-D49: Neoplasms | Bladder cancer | C67 | EGFR |
| L00-L99: Diseases of the skin and subcutaneous tissue | Psoriasis | L40 | EGFR |
| C00-D49: Neoplasms | Prostate cancer | C61 | EGFR |
| C00-D49: Neoplasms | Brain cancer | C71, D33 | EGFR; EGFR |
| C00-D49: Neoplasms | Breast cancer | C50 | CA9; EGFR; EGFR; EGFR |
| C00-D49: Neoplasms | Esophageal cancer | C15 | EGFR |